Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Significant Decrease in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 162,704 shares, a drop of 96.7% from the September 30th total of 4,925,958 shares. Approximately 2.9% of the shares of the company are short sold. Based on an average daily volume of 1,598,172 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on SLXN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. Maxim Group downgraded Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Silexion Therapeutics Price Performance

Shares of SLXN stock traded down $0.01 during trading on Tuesday, hitting $0.17. 633,628 shares of the stock traded hands, compared to its average volume of 3,377,303. The firm has a market capitalization of $922,960.00, a P/E ratio of -0.00 and a beta of -0.29. The firm’s fifty day moving average price is $0.31 and its 200-day moving average price is $7.45. Silexion Therapeutics has a 52-week low of $0.14 and a 52-week high of $35.00.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings data on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, topping the consensus estimate of ($21.20) by $16.03. As a group, equities research analysts expect that Silexion Therapeutics will post -4.70 earnings per share for the current year.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on developing targeted treatments for cancer, with an emphasis on tumors driven by mutations in the KRAS gene. The company’s primary focus is pancreatic cancer, a disease in which KRAS mutations are common and historically difficult to treat.

Silexion is developing RNA-based therapies designed to suppress cancer-promoting KRAS activity. Its pipeline has included siG12D-LODER, a locally administered therapy intended to deliver small interfering RNA against the KRAS G12D mutation, and SIL-204, a next-generation formulation designed to support broader or systemic delivery of KRAS-targeting treatment.

The company originated in Israel and has conducted its research and clinical development activities through Israeli and international collaborations and clinical programs.